Literature DB >> 6321678

Karnofsky Memorial Lecture. Breaking the cure barrier.

J F Holland.   

Abstract

Breaking the cure barrier is a biologic and a conceptual problem that has already been accomplished for several tumors. It is helpful to consider neoplasms in mathematical terms as many-celled tumors (polycytomas: kilocytomas, megacytomas, gigacytomas, and teracytomas). A new chemotherapeutic taxonomy recognizes curable, subcurable, and precurable cancers each with definable characteristics. A simplified technique of recognizing early cures is described by calculating the probability that an interruption in an exponential failure slope occurred by chance. Examples of cures of acute myelocytic leukemia, of superior chemotherapy for Hodgkin's disease in young adults, and of superior adjuvant chemotherapy for breast cancer are given. The interaction of surgery with chemotherapy is illustrated in pure form in acute myelocytic leukemia and in ovarian cancer. Curative chemotherapy is closer at hand than is generally believed. Nomograms for cure prediction are presented as inducements to contemplate curative approaches to cancer therapy.

Entities:  

Mesh:

Year:  1983        PMID: 6321678     DOI: 10.1200/JCO.1983.1.2.75

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Science, cynicism and scarcity.

Authors:  R Saginur
Journal:  Can J Infect Dis       Date:  1993-07

2.  Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer.

Authors:  R Rosso; A Alama; L Repetto; P F Conte
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Update on cancer chemotherapy: general considerations and breast cancer. Part II.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-09       Impact factor: 1.798

4.  Breast cancer surveillance--a cost-effective strategy.

Authors:  D V Schapira
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Antibody directed targeting of methotrexate-containing small unilamellar vesicles.

Authors:  M Singh; G Faulkner; T I Ghose; M Mezei
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Authors:  E Frei; S A Holden; R Gonin; D J Waxman; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

8.  Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin.

Authors:  M N Levine; M F Drummond; R J Labelle
Journal:  CMAJ       Date:  1985-11-15       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.